JP2019506863A - Ｐｄ−ｌ１及びｋｄｒに対する二重結合タンパク質 - Google Patents

Ｐｄ−ｌ１及びｋｄｒに対する二重結合タンパク質 Download PDF

Info

Publication number
JP2019506863A
JP2019506863A JP2018540412A JP2018540412A JP2019506863A JP 2019506863 A JP2019506863 A JP 2019506863A JP 2018540412 A JP2018540412 A JP 2018540412A JP 2018540412 A JP2018540412 A JP 2018540412A JP 2019506863 A JP2019506863 A JP 2019506863A
Authority
JP
Japan
Prior art keywords
seq
bispecific
nos
antibody
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018540412A
Other languages
English (en)
Japanese (ja)
Inventor
ゼンピン・ジュ
ダン・ルウ
Original Assignee
カドモン コーポレイション，リミティド ライアビリティ カンパニー
カドモン コーポレイション，リミティド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カドモン コーポレイション，リミティド ライアビリティ カンパニー, カドモン コーポレイション，リミティド ライアビリティ カンパニー filed Critical カドモン コーポレイション，リミティド ライアビリティ カンパニー
Publication of JP2019506863A publication Critical patent/JP2019506863A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018540412A 2016-02-02 2017-02-02 Ｐｄ−ｌ１及びｋｄｒに対する二重結合タンパク質 Pending JP2019506863A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662290350P 2016-02-02 2016-02-02
US62/290,350 2016-02-02
PCT/US2017/016230 WO2017136562A2 (en) 2016-02-02 2017-02-02 Bispecific binding proteins for pd-l1 and kdr

Publications (1)

Publication Number Publication Date
JP2019506863A true JP2019506863A (ja) 2019-03-14

Family

ID=59501012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540412A Pending JP2019506863A (ja) 2016-02-02 2017-02-02 Ｐｄ−ｌ１及びｋｄｒに対する二重結合タンパク質

Country Status (5)

Country Link
EP (1) EP3411068A4 (zh)
JP (1) JP2019506863A (zh)
CN (1) CN109310755A (zh)
EA (1) EA201891732A1 (zh)
WO (1) WO2017136562A2 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021535193A (ja) * 2019-08-09 2021-12-16 安徽瀚海博▲シィン▼生物技▲シゥー▼有限公司 新型構造の抗ｖｅｇｆ−抗ｐｄ１二重特異性抗体

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
KR20200016899A (ko) 2017-06-01 2020-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항-pdl1 항체, 및 이의 이용 방법
WO2019042153A1 (zh) 2017-09-01 2019-03-07 四川科伦博泰生物医药股份有限公司 重组双特异性抗体
CA3085467A1 (en) * 2018-02-28 2019-09-06 Ap Biosciences, Inc. Bifunctional proteins combining checkpoint blockade for targeted therapy
CN111196856A (zh) * 2018-11-19 2020-05-26 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体
CN111196855B (zh) * 2018-11-19 2022-11-15 三生国健药业（上海）股份有限公司 抗egfr/pd-1双特异性抗体
EP3891182A4 (en) 2018-12-03 2022-08-17 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd RECOMBINATION PROTEIN TARGETING PD-L1 AND VEGF
CN109776683B (zh) * 2019-03-19 2020-04-07 益科思特(北京)医药科技发展有限公司 一种双特异性抗体及其制备方法与应用
CA3144324A1 (en) * 2019-06-24 2020-12-30 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
CN110563849B (zh) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd1双特异性抗体
CN110498857B (zh) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd1双特异性抗体
CN110760517B (zh) * 2019-10-09 2022-04-29 天津大学 拮抗pd-1骆驼抗体类似物ap基因及蛋白和应用
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
CN113754772A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pdl1×kdr的双特异性抗体
CN113754773A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pd1×pdl1的双特异性抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051299A2 (en) * 2003-11-19 2005-06-09 Dyax Corp. Metalloproteinase-binding proteins
BRPI0715115A2 (pt) * 2006-08-03 2013-06-04 Vaccinex Inc anticorpo monoclonal isolado, molÉcula de Ácido nucleico isolada, vetor de expressço, cÉlula hospedeira, mÉtodos para tratar uma doenÇa, e para produzir um anticorpo monoclonal isolado, uso do anticorpo monoclonal isolado, e, composiÇço farmacÊutica
US7935345B2 (en) * 2007-05-21 2011-05-03 Children's Hospital & Research Center At Oakland Monoclonal antibodies that specifically bind to and neutralize bacillus anthracis toxin, compositions, and methods of use
RU2658504C9 (ru) * 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
KR101517320B1 (ko) * 2011-04-19 2015-05-28 메리맥 파마슈티컬즈, 인크. 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
DK2785375T3 (da) * 2011-11-28 2020-10-12 Merck Patent Gmbh Anti-pd-l1-antistoffer og anvendelser deraf
EP3556776A1 (en) * 2012-05-31 2019-10-23 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and vegf antagonists
HRP20220913T1 (hr) * 2012-10-05 2022-10-28 Kadmon Corporation, Llc Inhibitori rho kinaze
EP2903645A2 (en) * 2012-10-05 2015-08-12 Kadmon Corporation, LLC Treatment of ocular disorders
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
US10519247B2 (en) * 2013-11-01 2019-12-31 Board Of Regents,The University Of Texas System Targeting HER2 and HER3 with bispecific antibodies in cancerous cells
HRP20220214T1 (hr) * 2014-01-15 2022-04-29 Kadmon Corporation, Llc Imunomodulacijska sredstva

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021535193A (ja) * 2019-08-09 2021-12-16 安徽瀚海博▲シィン▼生物技▲シゥー▼有限公司 新型構造の抗ｖｅｇｆ−抗ｐｄ１二重特異性抗体
JP7052149B2 (ja) 2019-08-09 2022-04-11 安徽瀚海博▲シィン▼生物技▲シゥー▼有限公司 新型構造の抗ｖｅｇｆ－抗ｐｄ１二重特異性抗体
US11661454B2 (en) 2019-08-09 2023-05-30 Anhui Biox Vision Biological Technology Co., Ltd. Anti-VEGF-PD1 bispecific antibody with novel structure and use thereof

Also Published As

Publication number Publication date
WO2017136562A2 (en) 2017-08-10
EP3411068A2 (en) 2018-12-12
CN109310755A (zh) 2019-02-05
EA201891732A1 (ru) 2019-02-28
EP3411068A4 (en) 2020-01-29
WO2017136562A3 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
JP2019506863A (ja) Ｐｄ−ｌ１及びｋｄｒに対する二重結合タンパク質
JP6983918B2 (ja) 免疫調節剤
JP6779299B2 (ja) 抗ｐｄ−ｌ１抗体およびその使用
KR102651761B1 (ko) 암 치료용 결합 분자
AU2015316993B2 (en) Treatment regimens using anti-NKG2A antibodies
US20180244779A1 (en) Immunomodulatory agents
JP4864900B2 (ja) 血管内皮成長因子受容体−ｉに対する抗体
AU2020347473A1 (en) Treatment and prevention of cancer using HER3 antigen-binding molecules
WO2019185164A1 (en) Her3 antigen-binding molecules
EA039595B1 (ru) Нуклеиновые кислоты, кодирующие человеческие анти-vegfr-2/kdr-антитела
TW201920282A (zh) 抗egfr和pd-1的雙特異性抗體
CN114729053B (zh) 一种4-1bb结合蛋白及其应用